Drug Patent Watch

JUNE 22, 2024

Dabigatran etexilate mesylate is the generic ingredient in two branded drugs marketed by Alkem Labs Ltd, Apotex, Hetero Labs Ltd Iii, and Boehringer Ingelheim and, and is included in five NDAs. There are three patents protecting this compound. Drug patent litigation for DABIGATRAN ETEXILATE MESYLATE. Nine suppliers are listed for this compound.

Drugs 52

Drugs Marketing 52

Drugs.com

JUNE 22, 2024

SATURDAY, June 22, 2024 -- The pandemic highlighted the risk that air travel carries for the spread of infectious diseases, and that risk remains even though the health emergency has passed.“Airplanes have many touch points that are perfect for the.

Disease 52

Disease 52

Drug Patent Watch

JUNE 22, 2024

MOVANTIK (naloxegol oxalate) Valinor Patent: 7,056,500 Expiration: Jun 29, 2024 See More … For more information on how DrugPatentWatch can help with your pharmaceutical business intelligence needs, contact admin@DrugPatentWatch.com or visit www.DrugPatentWatch.

Pharmaceuticals 52

Pharmaceuticals Drugs 52

Drug Patent Watch

JUNE 22, 2024

This chart shows the pharmaceutical companies with the most patents in Serbia. Patents must be filed in each country (or, in some cases regional patent office) where patent protection is desired. For a global perspective, see the Drug companies with the greatest global patent coverage.

Pharmaceutical Companies 52

Pharmaceutical Companies Pharmaceuticals Drugs 52

Advertisement

Clinical trial data management is increasingly challenging as studies grow in complexity. Quickly accessing and analyzing study data is vital for assessing trial progress and patient safety. In this paper, we explore real-time data access and analysis for proactive study management. We investigate using adverse event (AE) data to monitor safety and discuss a clinical analytics platform that supports collaboration and data review workflows.

Clinical Trials